The Food and Drug Administration has cleared Novavax to move forward with testing of a combination vaccine for COVID-19 and ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

“As the industry transitions from traditional drug discovery and life sciences R&D to faster-paced, complex modalities, ...

The president-elect has said he’ll let Robert F. Kennedy Jr. “go wild” on healthcare, while many expect a leadership change ...

Past comments by Robert F. Kennedy Jr. hint at the ideas he might advocate for if given a role in the incoming Trump ...

Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is ...

Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Meanwhile, Sarepta is ...

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

Just three years removed from a lucrative IPO, the company will cut jobs for a third time and invest more heavily in cell ...

The selling price is an indication that the FDA’s planned sunsetting of the rare pediatric disease voucher program may be ...

Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

Quantiphi Global Head of Healthcare and Life Sciences Barinder Marhok said the partnership marries DDReg’s expertise in ...